This is a guest contribution from Simon Maina. KenolKobil is a leading oil distributor and marketer of petroleum and other associated products (e.g. petrol stations) in East Africa. Of late, it has also extended its footprint into Southern Africa with Zambia being its most recent investment. I find shares of the company particularly attractive because […]
When Africa’s richest man, Aliko Dangote, announced a 40% price cut on bags of Dangote Cement last week, Nigerian consumers rejoiced.
The stock market’s reaction, on the other hand, was decidedly less enthusiastic. Shares of the company have plunged nearly 19% since the news broke.
So, will the stock weigh down a portfolio’s performance going forward or does it have a solid foundation for market-beating gains? Let’s take a closer look.
This week GSK Nigeria (GLAXOSMI) announced that its profits through the first nine months of 2014 dropped 23% compared to the same time period last year.
The news came as a bitter pill to investors. The stock has fallen nearly 16% over the past thirty days and now trades at its lowest price in 16 months.
Are the shares bad medicine? Just what the doctor ordered? Or something in between?
Let’s have a closer look at the numbers and see what they reveal.
Stanbic IBTC is Nigeria’s best-performing bank stock. Its share price has climbed 40.5% this year and 55.4% over the past twelve months. Is it nearing the end of its run? Or is the market still offering investors a discount to the bank’s real worth?
Here, Godfrey Mwanza, CFA shows us how he values the company.